Tissue‐resident macrophages, marked by CD206, can shift phenotypically in response to local cues, complicating tumor dynamics.[14] This has led to therapies targeting macrophage activation, including metabolic reprogramming, to overcome their immunosuppressive effects and boost anti‐tumor immunity.[15, 16]. The gene discussed is MRC1; the disease is neoplasm.